Ronquest NA, Paret K, Gould I, Barnett CL, Mladsi (she/her) DM. The evolution of ICER's review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER's reports. J Manag Care Spec Pharm. 2021 Nov;27(11):1601-12. doi: 10.18553/jmcp.2021.27.11.1601
Herring WL, Mladsi DM. Equal value of life-years gained: comparison of methodologies for a cohort Markov model. Poster presented at the Virtual ISPOR 2021 Conference; May 2021. [abstract] Value Health. 2021 Jun; 24(Suppl 1):S176.
Yee KS, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Assessment of cognitive development in patients with neuronopathic Mucopolysaccharidosis II treated with intrathecal idursulfase-IT using Projected Retained Ability Score (PRAS): a post hoc analysis. Poster presented at the 2021 World Conference on Quality and Improvement; May 24, 2021.
Gandola AE, Ait Sarkouh R, Orfanos P, Bouisset F, Licitra L, Bourhis J, Mladsi D, Chirila C, Paret K, Barnett C. An early cost-effectiveness analysis of xevinapant in combination with chemo-radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck in United States. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Ronquest N, Paret K, Gould I, Barnett CL, Mladsi D. Effects of stakeholder engagement with Icer on cost-effectiveness of new interventions: lessons learned from a critical review of evaluations from 2018 to 2019. Presented at the Virtual ISPOR 2021 Conference; May 2021.
Yee K, Chirila C, Davenport E, Mladsi D, Barnett C, Kronenberger WG. Using projected retained ability score to assess cognitive development in patients with neuronopathic mucopolysaccharidosis II receiving intrathecal idursulfase-IT. Poster presented at the 2021 ACMG Annual Clinical Genetics Virtual Meeting; April 2021.
Mader G, Mladsi (she/her) D, Zhou X, Sanon M, Wang J, Willey C, Seliger S. Racial differences in mortality rates among elderly Non-ESRD CKD and ESRD patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD): study findings using data from the USRDS. Poster presented at the Virtual National Kidney Foundation 2021 Spring Clinical Meetings; April 2021.
Mladsi DM, Palmer WN, Miller D. Threshold pricing analysis: an economist's contribution to pharmaceutical pricing. Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.
Mladsi DM, Juniper MD, Roskell NS, Mitra D, Shannon PR, Wilson A, Garcia Cebrian A, Le KT. Pharmacological management of fibromyalgia in UK primary care. Poster presented at the19th Annual Clinical Meeting of the American Academy of Pain Management; September 2008. Nashville, TN.
Mladsi DM, Juniper MD, Roskell NS, Mitra D, Shannon PR, Wilson AG. The pharmacological management of fibromyalgia syndrome in the UK primary care setting. Presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.
Juniper MD, McCrink L, Mladsi DM, Le TK. The burden of fibromyalgia in France, Germany, Italy, Spain, and the UK: a literature-based review. Poster presented at the Annual Congress of the European League Against Rheumatism; June 2008. Paris, France.